

Executive Branch Personnel

Public Financial Disclosure Report:

Periodic Transaction Report (OGE Form 278-T)

Filer's Information

Watts, John

Senior Counselor, Bureau of Reclamation, Department of the Interior

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Watts, John [electronically signed on 06/08/2024 by Watts, John in Integrity.gov]

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Bowen, Eugene, Certifying Official [electronically signed on 07/03/2024 by Bowen, Eugene in Integrity.gov]

Other review conducted by

/s/ Smith, Sharnae, Ethics Official [electronically signed on 06/11/2024 by Smith, Sharnae in Integrity.gov]

U.S. Office of Government Ethics Certification

Transactions

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	NVIDIA Corp. (NVDA)	Purchase	05/15/2024	No	\$50,001 - \$100,000
2	StoneCo Ltd. Class A Common Shares (STNE)	Purchase	05/15/2024	No	\$15,001 - \$50,000
3	StoneCo Ltd. Class A Common Shares (STNE)	Purchase	05/15/2024	No	\$15,001 - \$50,000
4	StoneCo Ltd. Class A Common Shares (STNE)	Purchase	05/16/2024	No	\$1,001 - \$15,000
5	NVIDIA Corp. (NVDA)	Purchase	05/17/2024	No	\$50,001 - \$100,000
6	StoneCo Ltd. Class A Common Shares (STNE)	Purchase	05/17/2024	No	\$15,001 - \$50,000
7	Viridian Therapeutics Inc. Common Stock (VRDN)	Purchase	05/20/2024	No	\$1,001 - \$15,000
8	Viridian Therapeutics Inc. Common Stock (VRDN)	Purchase	05/21/2024	No	\$1,001 - \$15,000
9	Viridian Therapeutics Inc. Common Stock (VRDN)	Purchase	05/23/2024	No	\$1,001 - \$15,000
10	StoneCo Ltd. Class A Common Shares (STNE)	Purchase	05/23/2024	No	\$1,001 - \$15,000
11	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/28/2024	No	\$15,001 - \$50,000
12	HDFC Bank Limited Common Stock (HDB)	Purchase	05/28/2024	No	\$100,001 - \$250,000
13	Viridian Therapeutics Inc. Common Stock (VRDN)	Purchase	05/28/2024	No	\$1,001 - \$15,000
14	Viridian Therapeutics Inc. Common Stock (VRDN)	Purchase	05/28/2024	No	\$1,001 - \$15,000
15	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/28/2024	No	\$15,001 - \$50,000
16	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/28/2024	No	\$15,001 - \$50,000
17	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/28/2024	No	\$15,001 - \$50,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
18	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	05/28/2024	No	\$1,001 - \$15,000
19	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/28/2024	No	\$15,001 - \$50,000
20	HDFC Bank Limited Common Stock (HDB)	Purchase	05/28/2024	No	\$100,001 - \$250,000
21	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/28/2024	No	\$15,001 - \$50,000
22	Global Payments, Inc. (GPN)	Purchase	05/28/2024	No	\$1,001 - \$15,000
23	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/28/2024	No	\$15,001 - \$50,000
24	Intel Corp. (INTC)	Purchase	05/28/2024	No	\$15,001 - \$50,000
25	Sea Limited American Depositary Shares each representing one Class A Ordinary Share (SE)	Purchase	05/28/2024	No	\$15,001 - \$50,000
26	HDFC Bank Limited Common Stock (HDB)	Purchase	05/28/2024	No	\$50,001 - \$100,000
27	HDFC Bank Limited Common Stock (HDB)	Purchase	05/29/2024	No	\$50,001 - \$100,000
28	HDFC Bank Limited Common Stock (HDB)	Purchase	05/29/2024	No	\$50,001 - \$100,000
29	HDFC Bank Limited Common Stock (HDB)	Purchase	05/29/2024	No	\$50,001 - \$100,000
30	HDFC Bank Limited Common Stock (HDB)	Purchase	05/29/2024	No	\$50,001 - \$100,000
31	HDFC Bank Limited Common Stock (HDB)	Purchase	05/29/2024	No	\$50,001 - \$100,000
32	Meta Platforms Inc. Class A Common Stock (META)	Purchase	05/29/2024	No	\$15,001 - \$50,000

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
33	Meta Platforms Inc. Class A Common Stock (META)		Purchase	05/29/2024	No	\$15,001 - \$50,000
34	Meta Platforms Inc. Class A Common Stock (META)		Purchase	05/29/2024	No	\$1,001 - \$15,000
35	Meta Platforms Inc. Class A Common Stock (META)		Purchase	05/29/2024	No	\$1,001 - \$15,000
36	Meta Platforms Inc. Class A Common Stock (META)		Purchase	05/29/2024	No	\$15,001 - \$50,000
37	Meta Platforms Inc. Class A Common Stock (META)		Purchase	05/29/2024	No	\$1,001 - \$15,000
38	Amazon.com, Inc. (AMZN)		Purchase	05/29/2024	No	\$50,001 - \$100,000
39	Amazon.com, Inc. (AMZN)		Sale	05/30/2024	No	\$50,001 - \$100,000
40	Global Payments, Inc. (GPN)		Purchase	05/30/2024	No	\$1,001 - \$15,000
41	Intel Corp. (INTC)		Purchase	05/30/2024	No	\$15,001 - \$50,000
42	Viridian Therapeutics Inc. Common Stock (VRDN)		Purchase	05/30/2024	No	\$1,001 - \$15,000
43	HDFC Bank Limited Common Stock (HDB)		Purchase	05/30/2024	No	\$50,001 - \$100,000
44	Viridian Therapeutics Inc. Common Stock (VRDN)		Purchase	05/30/2024	No	\$1,001 - \$15,000
45	Viridian Therapeutics Inc. Common Stock (VRDN)		Purchase	05/30/2024	No	\$1,001 - \$15,000
46	Viridian Therapeutics Inc. Common Stock (VRDN)		Purchase	05/30/2024	No	\$1,001 - \$15,000
47	Inhibrx Inc. Common Stock (INBX)	See Endnote	Sale	05/31/2024	No	\$1,000,001 - \$5,000,000
48	Inhibrx Inc. Common Stock (INBX)	See Endnote	Sale	05/31/2024	No	\$500,001 - \$1,000,000

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
49	Inhibrx Inc. Common Stock (INBX)	See Endnote	Sale	05/31/2024	No	\$500,001 - \$1,000,000
50	Inhibrx Inc. Common Stock (INBX)	See Endnote	Sale	05/31/2024	No	\$250,001 - \$500,000
51	Inhibrx Inc. Common Stock (INBX)	See Endnote	Sale	05/31/2024	No	\$1,001 - \$15,000
52	Inhibrx Inc. Common Stock (INBX)	See Endnote	Sale	05/31/2024	No	\$50,001 - \$100,000
53	Inhibrx Inc. Common Stock (INBX)	See Endnote	Sale	05/31/2024	No	\$250,001 - \$500,000
54	Global Payments, Inc. (GPN)		Purchase	05/31/2024	No	\$1,001 - \$15,000
55	Advanced Micro Devices, Inc. (AMD)		Purchase	05/31/2024	No	\$50,001 - \$100,000
56	Viridian Therapeutics Inc. Common Stock (VRDN)		Purchase	05/31/2024	No	\$15,001 - \$50,000
57	Marvell Technology Group Ltd. (MRVL)		Purchase	05/31/2024	No	\$50,001 - \$100,000
58	Marvell Technology Group Ltd. (MRVL)		Purchase	05/31/2024	No	\$50,001 - \$100,000
59	Viridian Therapeutics Inc. Common Stock (VRDN)		Purchase	05/31/2024	No	\$1,001 - \$15,000
60	PagSeguro Digital Ltd. Class A Common Shares (PAGS)		Sale	06/03/2024	No	\$1,001 - \$15,000
61	PagSeguro Digital Ltd. Class A Common Shares (PAGS)		Sale	06/03/2024	No	\$1,001 - \$15,000
62	PagSeguro Digital Ltd. Class A Common Shares (PAGS)		Sale	06/03/2024	No	\$1,001 - \$15,000
63	PagSeguro Digital Ltd. Class A Common Shares (PAGS)		Sale	06/03/2024	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
64	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
65	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
66	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
67	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
68	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
69	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
70	Marvell Technology Group Ltd. (MRVL)	Purchase	06/03/2024	No	\$1,001 - \$15,000
71	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
72	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
73	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
74	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
75	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
76	United States Treasury Ser AL-2025 1.75000% 3/15/2025 CUSIP 91282CED9	Purchase	06/03/2024	No	\$250,001 - \$500,000
77	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
78	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
79	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
80	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
81	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
82	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
83	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
84	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$1,001 - \$15,000
85	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Purchase	06/03/2024	No	\$15,001 - \$50,000
86	Marvell Technology Group Ltd. (MRVL)	Purchase	06/03/2024	No	\$15,001 - \$50,000
87	Marvell Technology Group Ltd. (MRVL)	Purchase	06/03/2024	No	\$50,001 - \$100,000
88	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$15,001 - \$50,000
89	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
90	PagSeguro Digital Ltd. Class A Common Shares (PAGS)	Sale	06/03/2024	No	\$1,001 - \$15,000
91	Marvell Technology Group Ltd. (MRVL)	Purchase	06/03/2024	No	\$50,001 - \$100,000

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
92	United States Treasury Ser AL-2025 1.75000% 3/15/2025 CUSIP 91282CED9		Purchase	06/04/2024	No	\$250,001 - \$500,000
93	StoneCo Ltd. Class A Common Shares (STNE)		Purchase	06/04/2024	No	\$1,001 - \$15,000
94	Walgreens Boots Alliance, Inc. (WBA)		Sale	06/04/2024	No	\$1,001 - \$15,000
95	Marvell Technology Group Ltd. (MRVL)		Purchase	06/03/2024	No	\$50,001 - \$100,000
96	Marvell Technology Group Ltd. (MRVL)		Purchase	06/03/2024	No	\$1,001 - \$15,000
97	Marvell Technology Group Ltd. (MRVL)		Purchase	06/03/2024	No	\$50,001 - \$100,000
98	Marvell Technology Group Ltd. (MRVL)		Purchase	06/03/2024	No	\$50,001 - \$100,000
99	Wells Fargo & Co. (WFC)	See Endnote	Purchase	06/04/2024	No	\$1,001 - \$15,000
100	StoneCo Ltd. Class A Common Shares (STNE)		Purchase	06/05/2024	No	\$1,001 - \$15,000
101	Intel Corp. (INTC)		Purchase	06/06/2024	No	\$15,001 - \$50,000

Endnotes

PART	#	ENDNOTE
Transactions	47	Sanofi purchased Inhibrx for a combination of cash, shares in a spinoff of a new company, and a contingent valuation right that would include an additional payment on the timely achievement of a regulatory milestone. This transaction addresses the Inhibrx shares listed as asset 1.28 under "Other Assets" on my new entrant report.
Transactions	48	Sanofi purchased Inhibrx for a combination of cash, shares in a spinoff of a new company, and a contingent valuation right that would include an additional payment on the timely achievement of a regulatory milestone. This transaction addresses the Inhibrx shares listed as asset 2.9 under "Other Assets" on my new entrant report.

PART	#	ENDNOTE
Transactions	49	Sanofi purchased Inhibrx for a combination of cash, shares in a spinoff of a new company, and a contingent valuation right that would include an additional payment on the timely achievement of a regulatory milestone. This transaction addresses the Inhibrx shares listed as asset 3.7 under "Other Assets" on my new entrant report.
Transactions	50	Sanofi purchased Inhibrx for a combination of cash, shares in a spinoff of a new company, and a contingent valuation right that would include an additional payment on the timely achievement of a regulatory milestone. This transaction addresses the Inhibrx shares listed as asset 5.10 under "Other Assets" on my new entrant report.
Transactions	51	Sanofi purchased Inhibrx for a combination of cash, shares in a spinoff of a new company, and a contingent valuation right that would include an additional payment on the timely achievement of a regulatory milestone. This transaction addresses the Inhibrx shares listed as asset 1.3 under "Filer's Employment-Related Assets" on my new entrant report.
Transactions	52	Sanofi purchased Inhibrx for a combination of cash, shares in a spinoff of a new company, and a contingent valuation right that would include an additional payment on the timely achievement of a regulatory milestone. This transaction addresses the Inhibrx shares listed as asset 3.4 under "Filer's Employment-Related Assets" on my new entrant report.
Transactions	53	Sanofi purchased Inhibrx for a combination of cash, shares in a spinoff of a new company, and a contingent valuation right that would include an additional payment on the timely achievement of a regulatory milestone. This transaction addresses the Inhibrx shares listed as asset 4.6 under "Filer's Employment-Related Assets" on my new entrant report.
Transactions	99	Automatically reinvested dividends

Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

5 U.S.C. § 13101 et seq., and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. Failure to provide the requested information may result in separation, disciplinary action, or civil action. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with 5. U.S.C § 13107 and § 13122(b)(1) or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the

information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (4) to the National Archives and Records Administration or the General Services Administration in records management inspections; (5) to the Office of Management and Budget during legislative coordination on private relief legislation; (6) when the disclosing agency determines that the records are arguably relevant to a proceeding before a court, grand jury, or administrative or adjudicative body, or in a proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant to the proceeding; (7) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another, a public financial disclosure report and any accompanying documents, including statements notifying an employee's supervising ethics office of the commencement of negotiations for future employment or compensation or of an agreement for future employment or compensation; (8) to a Member of Congress or a congressional office in response to an inquiry made on behalf of and at the request of an individual who is the subject of the record; (9) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to this system of records; (10) on the OGE Website and to any person, department or agency, any written ethics agreement, including certifications of ethics agreement compliance, filed with OGE by an individual nominated by the President to a position requiring Senate confirmation; (11) on the OGE Website and to any person, department or agency, any certificate of divestiture issued by OGE; (12) on the OGE Website and to any person, department or agency, any waiver of the restrictions contained in Executive Order 13989 or any superseding executive order; (13) to appropriate agencies, entities and persons when there has been a suspected or confirmed breach of the system of records, the agency maintaining the records has determined that there is a risk of harm to individuals, the agency, the Federal Government, or national security, and the disclosure is reasonably necessary to assist in connection with the agency's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm; and (14) to another Federal agency or Federal entity, when the agency maintaining the record determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in responding to a suspected or confirmed breach or in preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity, the Federal Government, or national security. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.
